ChemoTech: Into Africa (Västra Hamnen)

Västra Hamnen Corporate Finance has released a research update on Scandiavian ChemoTech following its report for Q3 2018. We see exciting new opportunities following the company's entry into Africa and intention to explore the veterinary market. In the short term, we adjust our fair value range slightly to 17.00 – 25.70 SEK/share.

  • First order and distributor agreement in Africa
  • Exploring opportunities to enter veterinary market
  • We adjust our fair value range slightly lower

In Scandinavian ChemoTech’s report for Q4 and full year 2018, which was published yesterday, the company pointed towards interesting new opportunities for its technology. The most exciting item was the suggestion that its equipment for tumour control could find a market in household pets. Another piece of good news this week was the signing of its first distributor agreement in Africa, which came along with a first order from the continent. Thirdly, ChemoTech has been granted a loan conditional upon finding other financing, preferably new equity.

The full report is available here.

The research report is prepared as part of Market Focus, Västra Hamnen Corporate Fincance's commissioned research offering.

This is a press release from Västra Hamnen Corporate Finance AB. 
Web: vhcorp.se
Twitter: @vhcorp_se

Subscribe